Interstitial Lung Disease Alternative Therapy

Alternative Therapy for Treatment of Interstitial Lung Disease

The Lung Institute is proud to provide alternative therapy for the treatment of interstitial lung disease through the use of autologous stem cells. Interstitial lung disease is a broad term used to classify more than 100 different pulmonary disorders that directly affect how efficiently oxygen is absorbed into the lungs. The most prevalent type of interstitial lung disease is idiopathic pulmonary fibrosis, but other diseases under the umbrella of this condition include interstitial pneumonia, sarcoidosis, asbestosis and nonspecific interstitial pneumonitis.

Interstitial lung disease is a progressive condition, meaning that it continually worsens over time. While there is currently no cure, there is treatment available to help manage its symptoms. The stem cell therapy offered at the Lung Institute is aimed at slowing the progression of the disease and minimizing the symptoms associated with the condition, thus promoting a better quality of life for the patient. This form of treatment is unique in that it relies on the completely natural power of stem cells, which have the potential to self-renew and replicate to become any type of healthy bodily cell, such as a lung cell. Because the stem cells are entirely autologous – or derived from the patient’s own body – there is no risk of rejection and no long-term negative side effects.

We offer two different forms of stem cell treatment as an alternative therapy for interstitial lung disease:

• Venous stem cell therapy
• Bone marrow stem cell therapy

Both procedures are performed on an outpatient basis in one of our comfortable and modern facilities over the course of two days, and more than 80 percent of patients have reported improvement in their overall quality of life following treatment at the Lung Institute.

If you would like to learn more about the stem cell procedures we offer as an alternative therapy for treating interstitial lung disease, call the Lung Institute team today at (800) 729-3065.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.